HOPX has been identified as one of the most cancer-specific hypermethylated biomarkers, with hypermethylation detected in 90% of primary gastric tumors [32], 62.5% (10/16) colorectal [33], and 69% (9/14) endometrial cancers [34], the latter was considerably higher than the 39% hypermethylation in our OC samples. This evidence concerns the gene HOPX and endometrial cancer.